SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gara JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004; 279: 27372746.
  • 2
    Heshat M, Mellinghoff I, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA. 2001; 98: 1031410319.
  • 3
    Schmezle T, Hall MN. TOR, a central controller of cell growth [review]. Cell. 2000; 103: 253262.
  • 4
    Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy [review]. Curr Opin Pharmacol. 2003; 3: 371377.
  • 5
    Lu Y, Yu Q, Liu JH, et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem. 2003; 278: 4005740066.
  • 6
    Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy [review]. Oncogene. 2000; 19: 66806686.
  • 7
    Raymond E, Alexandre J, Depenbrock H, et al. CCI-779, a rapamycin analog with antitumor activity: a phase I study utilizing a weekly schedule [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 187a.
  • 8
    Peralba JM, DeGraffenried L, Friedrichs W, et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res. 2003; 9: 28872892.
  • 9
    Dutcher JP, Hudes G, Motzer R, et al. Preliminary report of a phase 1 study of intravenous (IV) CCI-779 given in combination with interferon-α (IFN) to patients with advanced renal cell carcinoma (RCC) [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 213.
  • 10
    Chan S, Scheulen ME, Johnston S, et al. A phase 2 study of two dose levels of CCI-779 in locally advanced or metastatic breast cancer failing prior anthracycline and/or taxane regimens [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 193.
  • 11
    Atkins MB, Hidalgo M, Stadler W, et al. Ranomized phase 2 study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004; 22: 909918.
  • 12
    Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updates. 2001; 4: 378391.